The latest research outcomes for treosulfan presented at the 48th EMBT conference

Data presented from prospective studies demonstrated the benefits of treosulfan based conditioning in both adult and paediatric patients.

medac Pharma UK attended the European Society of Blood and Bone Marrow Transplantation conference last month in a virtual capacity where the latest data on treosulfan based conditioning was presented. 3 out of the 6 presentations data were based on medac GmbH sponsored studies.

Professor Karl-Walter Sykora (Hannover, Germany) revealed the results of a randomised phase II study (MC-FludT.16/NM)1 which compared treosulfan and busulfan based conditioning in paediatric patients with non-malignant diseases. Conditioning with treosulfan led to survival rates of 96.1% after 12 months compared to 88.0% with busulfan. Treosulfan conditioning also led to a lower rate of transplant related morality at 3.9% compared to 12% with busulfan2.

The next 2 sessions included results from the pivotal phase III study MC-FludT.14/L3 presented by Dr Matthias Stelljes (Munster, Germany) and Prof. Friedrich Stölzel (Dresden, Germany). This study investigated the efficacy of treosulfan based condition for older and comorbid patients with MDS and patients with AML compared to busulfan based conditioning4,5. The data confirmed the clinically relevant survival benefits of treosulfan for both cohorts.

As well as the medac GmbH sponsored sessions, in total 14 abstracts and posters at the conference were focused on results surrounding treosulfan based conditioning. This number reveals the increasing interest in this treatment option for patients around the world.

About Trecondi®:
​Trecondi® in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients with malignant and non-malignant diseases, and in paediatric patients older than one month with malignant diseases.6

It is the only conditioning regimen to be NICE recommended.7

References

  1. NCT02349906, EudraCT Number: 2013-005508-33
  2. K.-W. Sykora et al. ;EBMT; 2022 [cited 2022 Mar 23]. Available from: URL: https://ebmt2022.abstractserver.com/program/#/details/presentations/999.
  3. NCT00822393, EudraCT Number: 2008-002356-18
  4. M. Stelljes et al: EBMT; 2022 [cited 2022 Mar 23]. Available from: URL: https://ebmt2022.abstractserver.com/program/#/details/presentations/841.
  5. F. Stölzel et al: EBMT; 2022 [cited 2022 Mar 23]. Available from: URL: https://ebmt2022.abstractserver.com/program/#/details/presentations/904
  6. https://www.medicines.org.uk/emc/search?q=%22Trecondi%22
  7. https://www.nice.org.uk/guidance/ta640

 

Get updates in your mailbox

By clicking "Subscribe" I confirm I have read and agree to the Privacy Policy.

About medac Pharma

medac Pharma is a privately owned, pharmaceutical company specialising in product development and the treatment of diseases within the key areas of oncology, autoimmune and urology.

medac GmbH was originally founded in Germany in 1970 and the UK operation was established in 1993. Since then we have become known for developing innovative products, especially in less common indications, which have resulted in a comprehensive portfolio of pharmaceutical products which help make a positive difference to the lives of your patients. We are committed to supplying therapeutic products and providing the diagnostic resources to identify diseases. We continue to invest in our manufacturing and logistic capabilities to ensure we meet the increasing demand of both healthcare professionals and patients’ needs.

Contact

Scion House Stirling University Innovation Park Stirling FK9 4NF

01786 458086

[email protected]

www.medacpharma.co.uk